Clovis looks beyond ovarian cancer for PARP inhibitor Rubraca

10 October 2018

American PARP inhibitor specialist Clovis Oncology (Nasdaq: CLVS) will present four posters related to the Rubraca (rucaparib) development program at the 2018 European Society of Medical Oncology congress.

Clovis will present initial results from the Phase II TRITON2 clinical trial in advanced mCRPC, data from which formed the basis for the recently-granted US Food and Drug Administration Breakthrough Designation in this indication.

The Boulder, Colorado-based firm will also provide genomic profiling data from patients who were screened following progression on prior therapy for enrollment in TRITON2 or the Phase III TRITON3 study.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK